re.Mind Capital Limited is an early-stage venture investor dedicated to mental health, brain health and human flourishing. Its public strategy spans brain-computer interfaces, personalized diagnostics and treatment selection, new pharmacology and treatment modalities, including neuromodulation, neurofeedback and digital mental healthcare. Its published portfolio includes AI-driven drug discovery, digital phenotyping, computational neuroscience, medical micro-robotics and implantable brain interfaces. The firm is part of Christian Angermayer’s Apeiron investment network, with a London office and a Maltese legal address. Its public team page names co-founders Christian Angermayer, Max de Vere and Jan Hardorp, plus investor Joao Barbosa da Silva; Katherine Jones’s separate 2023 representation is a historical affiliation. Registered vehicles include a Maltese master fund and feeder, and a July 2026 disclosed Bridge I special-purpose vehicle with USD1,012,500 fully sold. A co-investor’s historical USD150 million managed-capital description does not establish the first fund’s final close. The firm is distinct from the school communications company Remind.
Founded —
Type Venture capital 3 re.Mind Capital Bridge I a Series of CGF2021 LLC 2026-07-06 2026-07-06 $1M SEC July6,2026 FormD reports USD1,012,500 fully sold to one investor, with no remaining offering. First saleJune30,2026. The filing states USD12,500 covers organizational/operating expenses. This is SPV fundraising, not proof of its direct ticket into Bridge Neuro; neither a net1M companycheck nor a new companyfinancing round is inferred. SEC submissions show no subsequent amendment at review.
APEIRON FEEDER SICAV P.L.C. - re.Mind Capital Feeder Fund ONE — — Active Maltese feeder vehicle verified by GLEIF LEI529900SK4DFNFPDXAD54 and Austrian FMA cross-border register. Not a new additive fund strategy or a documented final cash close. No size inferred from Samara’s individual holding valuation.
Apeiron SICAV Limited - re.Mind Capital Fund One — — Exact active Maltese master fund vehicle verified by GLEIF LEI5299009HIB3509P6BC38 and primary US securities holdings disclosures. This is the firm’s first master fund, distinct from its feeder vehicle. HTGF’s January2022 historical USD150M managed-capital description is preserved as context, not proof of final closed commitments. Secondary USD120M/650M claims and Samara’s individual NAV/holding value are not the whole-fund size.
SHOW MORE
$18M 2024-01-24 Motif Neurotech Arboretum Ventures , Dolby Family Ventures , KdT Ventures , Satori Neuro , re.Mind Capital , Max Hodak , Divergent Capital , TMC Innovation , PsyMed Ventures , Empath Ventures , Capital Factory $41M 2023-01-25 Precision Neuroscience Forepont Capital Partners , Mubadala Capital , Draper Associates , Alumni Ventures , re.Mind Capital , Steadview Capital , B Capital $30M 2022-11-08 Sensorium Therapeutics Santé Ventures , Ocama Partners , CU Healthcare Innovation Fund , re.Mind Capital $— 2022-01-12 CereGate 468 Capital , re.Mind Capital , TruVenturo , Heal Capital , High-Tech Gründerfonds $40M 2021-06-03 Synchron Khosla Ventures , Forepont Capital Partners , ID8 Investments , Shanda Group , General Advance , Subversive Capital , re.Mind Capital , Arani Bose , Thomas Reardon , Neuro Technology Investors , METIS Innovative , University of Melbourne $10M 2021-05-19 Blackrock Neurotech re.Mind Capital , Peter Thiel , Tim Sievers , University Venture Fund II $— Unknown date OpenBCI re.Mind Capital $34M 2022-10-25 Alto Neuroscience Lightswitch Capital , re.Mind Capital , What If Ventures , Windham Capital Partners , Valor Equity Partners , Gaingels , Amit Etkin $— 2022-07-28 iLoF Faber , Lunar Ventures , Alter Global , M12 , Scale Venture Partners , Quiet Capital , re.Mind Capital $31M 2021-10-14 Alto Neuroscience re.Mind Capital , What If Ventures , Stanford University , Gwill York $— 2021-10-07 Neumora Therapeutics, Inc. ARCH Venture Partners , Catalio Capital Management , F-Prime Capital , Alexandria Venture Investments , Polaris Innovation Fund , re.Mind Capital $70M 2021-09-27 Delix Therapeutics PsyMed Ventures , Ocama Partners , Vertical Venture Partners , re.Mind Capital $13M Unknown date Bridge Neurotech General Catalyst , re.Mind Capital , Scott Sandell , Sunflower Capital (US) $— Unknown date TRIPP Niremia Collective , re.Mind Capital $— Unknown date neurocare group re.Mind Capital $— Unknown date Bionaut Labs Compound , re.Mind Capital $— 2026-03-02 Neurocast.ai re.Mind Capital
SHOW MORE
team@apexlogos.ai · yesterday
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Fund size and stages
| Item | Supported conclusion | Source/date and limits |
| --- | --- | --- |
| First fund | USD 150 million managed by the first re.Mind fund | [HTGF CereGate financing release](https://www.htgf.de/en/htgf-financing-ceregate/ ), 2022-01-12. This co-investor announcement describes an operating fund and around 20 portfolio companies; it does not supply a formal final-close date or commitments schedule. |
| Earlier founder statement | Christian Angermayer describes a new USD 150m fund funded substantially by himself and other investors | [Founder article](https://www.linkedin.com/pulse/those-who-cannot-remember-past-condemned-repeat-christian-angermayer ), 2021-era article, exact day not recovered, accessed 2026-10-06. Consistent with HTGF, not a second fund. |
| Newer fund/current AUM | Not verified | Searches for newer funds and a USD 650m claim did not recover a reliable fund announcement. Do not use investee rounds, Apeiron group AUM or the Signal check range as fund size. |
| Current mandate | Early-stage investor focused on mental/brain health | [Official root](https://remind.vc/ ), undated, accessed 2026-10-06. No firm-wide exclusive series boundary stated. |
| Historical scope | An investee release says re.Mind invests at any stage; transactions include seed, Series A and Series B | [neurocare financing announcement](https://www.neurocaregroup.com/news-insights/neurocare-announces-financing-round-with-bm-t-and-strategic-investor-apeiron-re-mind ), 2020-era release, exact day not recovered, accessed 2026-10-06; dated transactions below. Retain the historical/current distinction. |
Funds recorded in Adex after this review:
| Fund | Disclosed amount | Announcement / filing date |
| --- | --- | --- |
| re.Mind first fund | Undisclosed / unverified | Unknown | SHOW MORE
team@apexlogos.ai · yesterday
Match research 2026-10-06 / GoldireMindCapital / sha256:822a8600e822f41c20d3691df73948973f507d87bd46606714e54b80f972ede9 / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
| **Neurocast.ai** | [Company announcement syndicated by StreetInsider](https://www.streetinsider.com/Press%2BReleases/re.Mind%2Bjoins%2BNeurocast.ai%2Bas%2Binvestor%2Bto%2Badvance%2Bcontinuous%2Bbrain%2Bhealth%2Bmonitoring/26085070.html ), dateline 2026-03-02 (US display timestamp March 1), announces re.Mind investment; amount undisclosed. | Brain-health monitoring using passive smartphone behavior/digital biomarkers; neuroscience/digital-health adjacency rather than implanted neural sensing. Source says FDA-registered, which should not be recast as FDA-cleared/approved. Stage not specified. This newer transaction counters stale aggregator inactivity claims. |
## Portfolio-only leads, conflicts and missing information
- The [official detailed homepage](https://remind.vc/homepage/ ) describes additional portfolio technology themes and the [firm’s LinkedIn BCI post](https://www.linkedin.com/posts/remindvc_sxsw-bci-neurotech-activity-7041807725571264513-Xcx6 ) names Synchron and OpenBCI alongside Blackrock, Precision and CereGate (2023-era post, exact day not recovered, accessed 2026-10-06). Treat Synchron/OpenBCI as direct firm portfolio claims; round/date/check still need verification. Synchron’s [2022 Series C release hosted by investor Reliance](https://www.ril.com/sites/default/files/2023-01/MR15122022.pdf ) does not name re.Mind, so do not assign that round from portfolio membership alone.
- [Gaebler](https://www.gaebler.com/VC-Investors-0241E0EE-9405-4581-95A4-2DEEE5E41B1F-re-Mind-Capital ) (undated, accessed 2026-10-06) labels the firm inactive and has no fund closing recorded. This conflicts with the official live early-stage mandate and 2026 Neurocast announcement; an aggregator status is insufficient to conclude inactivity.
- [Capital Atlas](https://capitalatlas.ai/funds/428013 ) (undated, accessed 2026-10-06) displays USD 650m latest fund and USD 4.2bn AUM without a named fund/vintage/close supporting those numbers. They remain unverified and should not replace USD 150m first-fund evidence. Potential broader-group/investee conflation cannot be resolved from the page.
- In the snapshot, iLoF round metadata includes Faber and Lunar-specific evidence attached to a shared round. Those prove neither re.Mind’s check nor its leadership; the independent named investor list resolves participation. Neumora’s goldi.ai/ARCH metadata should be replaced in later review with the official company investor list.
- The 2020 founding year appears in directories but was not established by a dated formation record in this review. Current legal fund vehicle, closed commitments, fee-paying AUM, dry powder, next fund, firm-wide check policy and individual checks remain undisclosed/unverified.
- Wider Apeiron/Angermayer investments and founder history (including atai/Compass) are not automatically re.Mind investments. Other leads such as Delix, Sensorium and CB Therapeutics need transaction-level verification before importing; official stories/news alone may describe sector news rather than an attributable investment.
## Concrete notes for later Adex review
Preserve exact ID `GoldireMindCapital`. Consider official website/description, current early-stage strategy and the dated USD 150m first-fund disclosure with status caveat. Keep the verified Precision/Blackrock participation records and strengthen Neumora/iLoF citations. Review additional CereGate, Motif, neurocare and Neurocast relationships using the sources above, preserving unknown series/checks and brain-health adjacency. Keep Signal check values as attributed profile claims. Do not import unsupported USD 650m fund/AUM or infer a 2022 Synchron round. All external sources were accessed 2026-10-06; publication dates and access limitations are stated above. SHOW MORE
team@apexlogos.ai · yesterday
Match research 2026-10-06 / GoldireMindCapital / sha256:822a8600e822f41c20d3691df73948973f507d87bd46606714e54b80f972ede9 / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# re.Mind Capital
Research completed: 2026-10-06. Exact Adex ID: `GoldireMindCapital`. Canonical Adex URL: https://adex.page/firms/GoldireMindCapital . This is research for later review; no Adex/database changes were made.
## Identity and summary
re.Mind Capital is a venture investor dedicated to mental and neurological health, within Christian Angermayer’s Apeiron Investment Group. Its official detailed homepage names Christian Angermayer, Max de Vere and Jan Hardorp as co-founders/general partners, gives a London office and a Maltese company footer. The root website now describes an early-stage focus on mental health, brain health and human flourishing. This is re.Mind, not the unrelated real-estate business REM Capital, and `Goldi` in the immutable Adex ID is not its brand. Sources: [official root](https://remind.vc/ ) and [detailed homepage](https://remind.vc/homepage/ ), undated, accessed 2026-10-06.
Strong verified fit: direct BCI and neuromodulation investments in Blackrock Neurotech, Precision Neuroscience, CereGate and Motif Neurotech, alongside scientific drug-discovery/diagnostics exposure. Latest-known supported fund-size disclosure is USD 150 million for its first fund, reported in January 2022; a newer fund size was not verified.
## Starting evidence: Adex and NFX Signal
Saved source: `_sources/GoldireMindCapital.adex.json`, retrieved 2026-10-06 at 19:29:05 UTC from read-only Adex MCP Search. The record name is re.Mind Capital; description/founding date are blank, check-size fields null, and no NFX URL is supplied. Its generic source is https://goldi.ai/ . Four investment participations are present: Blackrock Neurotech (2021-05-19, USD 10m financing, lead), Neumora (2021-10-07, Series A), iLoF (2022-07-28, seed), Precision Neuroscience (2023-01-25, USD 41m Series B, participant). Snapshot claims are baseline evidence only.
NFX was searched for the firm and named founders/team. A generic list led to the directly readable [Signal firm page](https://signal.nfx.com/firms/re-mind-capital-ltd ) (undated, accessed 2026-10-06). It locates the firm in London and names Max de Vere, partner, and Joao Barbosa da Silva, investor. Both show USD 100k–5m ranges and USD 1.5m sweet spots, with seed/pre-seed medical devices, biotech, consumer health and digital health categories. These are individual profile claims, not independently verified firm limits. Intro paths require Gmail sign-in. The generic marketing-tech investor-list inclusion is not evidence of a core marketing-tech mandate.
## Fund size and stages
| Item | Supported conclusion | Source/date and limits |
| --- | --- | --- |
| First fund | USD 150 million managed by the first re.Mind fund | [HTGF CereGate financing release](https://www.htgf.de/en/htgf-financing-ceregate/ ), 2022-01-12. This co-investor announcement describes an operating fund and around 20 portfolio companies; it does not supply a formal final-close date or commitments schedule. |
| Earlier founder statement | Christian Angermayer describes a new USD 150m fund funded substantially by himself and other investors | [Founder article](https://www.linkedin.com/pulse/those-who-cannot-remember-past-condemned-repeat-christian-angermayer ), 2021-era article, exact day not recovered, accessed 2026-10-06. Consistent with HTGF, not a second fund. |
| Newer fund/current AUM | Not verified | Searches for newer funds and a USD 650m claim did not recover a reliable fund announcement. Do not use investee rounds, Apeiron group AUM or the Signal check range as fund size. |
| Current mandate | Early-stage investor focused on mental/brain health | [Official root](https://remind.vc/ ), undated, accessed 2026-10-06. No firm-wide exclusive series boundary stated. |
| Historical scope | An investee release says re.Mind invests at any stage; transactions include seed, Series A and Series B | [neurocare financing announcement](https://www.neurocaregroup.com/news-insights/neurocare-announces-financing-round-with-bm-t-and-strategic-investor-apeiron-re-mind ), 2020-era release, exact day not recovered, accessed 2026-10-06; dated transactions below. Retain the historical/current distinction. |
## Verified previous deep-tech and direct neurotech investments
All round totals below are company-wide financing amounts, not re.Mind’s individual check. Classification is a research interpretation based on the described technology; it does not establish clinical efficacy or regulatory approval.
| Company | Investment attribution and date | Technology relevance and caveats | Supporting source |
| --- | --- | --- | --- |
| **Blackrock Neurotech** | Led closed USD 10m financing announced 2021-05-19; Angermayer and Hardorp joined the board | Direct neurotech and deep tech: implanted electrode arrays/BCI enable communication and control of external devices. No series label provided. | [Official company release](https://blackrockneurotech.com/insights/blackrock-neurotech-closes-10m-financing-round-to-advance-development-of-its-world-leading-brain-computer-interface-bci-technology/ ), 2021-05-19. Search-index text was readable; direct open initially returned an internal error. |
| **Precision Neuroscience** | Named participant in USD 41m Series B led by Forepont, 2023-01-25 | Direct neurotech and deep tech: thin-film cortical microelectrode interface designed for high-resolution brain recording and reversible placement. | [Company-issued GlobeNewswire release](https://www.globenewswire.com/news-release/2023/01/25/2595114/0/en/precision-neuroscience-raises-41-million-to-build-and-scale-the-next-generation-of-treatments-for-neurological-illnesses.html ), 2023-01-25, directly read. |
| **CereGate** | Co-led financing with 468 Capital, announced 2022-01-12; amount/series undisclosed in source | Direct neurotech: software-based computer-to-brain interface using neuromodulation devices; applications described for deep brain stimulation and spinal cord stimulation. Software here interfaces with neural stimulation hardware rather than ordinary SaaS. | [HTGF official co-investor release](https://www.htgf.de/en/htgf-financing-ceregate/ ), 2022-01-12. |
| **Motif Neurotech** | Named new investor in USD 18.75m Series A led by Arboretum, 2024-01-24 | Direct neurotech and deep tech: miniature DOT brain pacemaker/microstimulator, initially being developed for treatment-resistant depression. | [Transaction counsel Wilson Sonsini announcement](https://www.wsgr.com/print/v2/content/49016904/Wilson-Sonsini-Advises-Motif-Neurotech-on-%2418.75-Million-Series-A-Financing.pdf ), document date 2024-01-24; search-index readable. |
| **neurocare group** | Company explicitly announces new strategic investor re.Mind and refers to it as an anchor investor; amount/series undisclosed | Direct neuromodulation exposure through personalized clinical care and a DTx platform. A mixed provider/platform investment; distinguish delivery of neurostimulation and neurofeedback from a pure implant/device manufacturer. | [Official neurocare announcement](https://www.neurocaregroup.com/news-insights/neurocare-announces-financing-round-with-bm-t-and-strategic-investor-apeiron-re-mind ), 2020-era release, exact day not recovered, accessed 2026-10-06. |
## Verified scientific investments adjacent to direct neurotech
| Company | Investment and supporting dates | Classification and attribution |
| --- | --- | --- |
| **iLoF** | Named re.Mind participant, funding announced 2022-07-28. [EU-Startups reporting](https://www.eu-startups.com/2022/07/digital-health-startup-ilof-secures-e4-89-million-to-accelerate-personalised-drug-discovery/ ) reports about EUR 4m equity plus EUR 880k ERDF grant, headline EUR 4.89m; [official re.Mind stories](https://remind.vc/stories/ ) features it on 2022-08-01. | Deep tech: photonics/optical biological fingerprints and AI for biomarker libraries and personalized drug-development screening. Alzheimer’s applications make it neuroscience-adjacent, not a direct BCI or neural stimulation investment. The article mixes currency wording in one sentence; retain approximate EUR figures and separate grant/equity. |
| **Neumora Therapeutics** | [Official company launch release](https://neumoratx.com/news/neumora-therapeutics-launches-to-pioneer-a-new-era-of-precision-medicines-for-brain-diseases/ ), 2021-10-07, explicitly names re.Mind Capital (Apeiron) in the ARCH-led Series A syndicate and reports over USD 500m raised including separate USD 100m Amgen equity. | Deep scientific biotech: precision medicines/data science for neuropsychiatric and neurodegenerative disorders. Neuroscience drug discovery, not direct BCI/neural interface. Do not record the whole USD 500m as re.Mind’s check or assume it is solely Series A. | SHOW MORE
team@apexlogos.ai · 22 days ago
MATCH 
Christian AngermayerCo-founder; General Partner
Jan HardorpCo-founder; General Partner
Joao Barbosa da SilvaInvestor (public team page labels Investment Associate)
Max de VereCo-founder; General Partner
Forepont Capital Partners
Precision Neuroscience$41M · 2023-01-25
Synchron$40M · 2021-06-03
Ocama Partners
Sensorium Therapeutics$30M · 2022-11-08
Delix Therapeutics$70M · 2021-09-27
PsyMed Ventures
Motif Neurotech$18M · 2024-01-24
Alto Neuroscience$34M · 2022-10-25
468 Capital
CereGate$— · 2022-01-12
Neumora Therapeutics, Inc.$— · 2021-10-07
iLoF$— · 2022-07-28
Alumni Ventures
Amit Etkin
Arboretum Ventures
ARCH Venture Partners
B Capital
Capital Factory
Catalio Capital Management
Compound
Bionaut Labs$— · Unknown date
CU Healthcare Innovation Fund
Dolby Family Ventures
Draper Associates
General Catalyst
Bridge Neurotech$13M · Unknown date
Gwill York
High-Tech Gründerfonds
KdT Ventures
Khosla Ventures
Lightswitch Capital
Lunar Ventures
Max Hodak
METIS Innovative
Mubadala Capital
Neuro Technology Investors
Niremia Collective
TRIPP$— · Unknown date
Peter Thiel
Blackrock Neurotech$10M · 2021-05-19
Quiet Capital
Santé Ventures
Satori Neuro
Scott Sandell
Steadview Capital
Sunflower Capital (US)
Thomas Reardon
Tim Sievers
TruVenturo
University Venture Fund II
Vertical Venture Partners
